0001628280-24-007711.txt : 20240228 0001628280-24-007711.hdr.sgml : 20240228 20240228175237 ACCESSION NUMBER: 0001628280-24-007711 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240213 FILED AS OF DATE: 20240228 DATE AS OF CHANGE: 20240228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arbet-Engels Christophe CENTRAL INDEX KEY: 0001802615 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 24697586 MAIL ADDRESS: STREET 1: C/O MILLENDO THERAPEUTICS, INC. STREET 2: 110 MILLER AVENUE, SUITE 100 CITY: ANN ARBOR STATE: MI ZIP: 48104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001501697 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 273181608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 BUSINESS PHONE: 857-529-8300 MAIL ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 FORMER COMPANY: FORMER CONFORMED NAME: Arsanis, Inc. DATE OF NAME CHANGE: 20100920 4/A 1 wk-form4a_1709160742.xml FORM 4/A X0508 4/A 2024-02-13 2024-02-16 0 0001501697 X4 Pharmaceuticals, Inc XFOR 0001802615 Arbet-Engels Christophe C/O X4 PHARMACEUTICALS INC. 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 0 1 0 0 Chief Medical Officer 0 Stock Appreciation Right 0.921 2024-02-13 4 A 0 180816 0 A 2034-02-13 Common Stock 180816 180816 D This Form 4 amendment is being filed to correct the number of stock appreciation rights awarded to the Reporting Person on February 13, 2024. The original Form 4 filed on February 16, 2024 inadvertently reported the number of stock appreciation rights awarded as 475,831 due to an administrative error. The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date. /s/ Adam S. Mostafa, attorney-in-fact 2024-02-28